⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 3, 2026Expert Opinion on Investigational Drugs

Progress of investigational bromodomain and extra-terminal domain inhibitors for myelofibrosis therapy

N. Beygui Michael Rogers Veer Shah Megan Metzger John Mascarenhas

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effectiveness of bromodomain and extra-terminal domain inhibitors in myelofibrosis therapy.
Investigation of pan-BET inhibitors like Pelabresib and their clinical trials.
Exploration of combination therapies using BET inhibitors and JAK inhibitors.
Assessment of both monotherapy and combination approaches in ongoing trials.
Pelabresib shows clinical benefits and is the most advanced pan-BET inhibitor in trials.
The role of BET inhibitors in modifying disease biology remains to be conclusively determined.
Potential for substantial anti-clonal activity to impact clinical outcomes is under investigation.

Implication

Research explores BET protein inhibitors to improve outcomes in myelofibrosis, indicating potential for better therapies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Beygui et al. (2026) studied this question.

synapsesocial.com/papers/698584b78f7c464f2300829c https://doi.org/10.1080/13543784.2026.2627204

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract LB159: Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis2024
2Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosisEarly-Phase Clinical Trial · 2026 · 5 citations
3Inhibition of Bromodomain and Extra-Terminal Domain Proteins in Solid Tumors: Advances, Challenges, and Future DirectionsHuman Clinical Trial · 2026
4The Path Forward in MF: Small Molecules in the LimelightClinical Trial · 2026
5BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsHuman Clinical Trial · 2022 · 21 citations

More related papers

Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence2015
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors2016
EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)2025

More from Expert Opinion on Investigational Drugs

Designing for success in early phase haemophilia clinical trials: historical lessons and emerging principles for next generation therapeuticsThu,
Targeting the proteasome in Leishmania donovani : developments from preclinical to Phase I and ii trialsWed,